Clinical trial · Interventional
The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer
The Value of DWI-MRI(Diffusion-weighted Imaging) in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer
NCT03088163CI-TRIAL-00026600unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed to evaluate the value of DWI-MRI (Diffusion weighted magnetic resonance imaging) in predicting the efficacy of liver metastases after chemotherapy in colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DWI-MRI | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diffusion weighted magnetic resonance imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DWI-MRI
- interventionNames
- Device: Diffusion weighted magnetic resonance imaging
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 2 months
- description
- the response rate predicted by DWI-MRI
Secondary outcomes (2)
- measure
- Progression free survival
- timeFrame
- 2 months
- measure
- Overall survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * aged ≥18 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma * Eastern Cooperative Oncology Group performance status of 0 to 2 * life expectancy of ≥ 3 months * at least one measurable liver metastatic lesion in MRI (≥10mm) * have adequate bone marrow, hepatic, and renal function * previously received no palliative chemotherapy Exclusion Criteria: * patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction * patients with symptomatic brain metastases * active clinical severe infection * have contraindication of MRI screening
References
Publications (0)
Data not yet available
No reference posted for this study.